Fibrogenincis A Biopharmaceutical Company Based In San Franciscocaliforniafounded In 1993The Company Focuses On Developing And Commercializing Innovative Therapeutics For Cancer And Anemiafibrogen Is Dedicated To Advancing Researchconducting Clinical Trialsand In Licensing New Product Candidates To Meet Significant Medical Needs The Company S Product Pipeline Features Several Key Candidatesincluding Roxadustatan Oral Treatment For Anemia Related To Chronic Kidney Diseaseand Pamrevlumaban Antibody Targeting Connective Tissue Growth Factor For Pancreatic Cancerfibrogen Also Has Additional Pipeline Products Aimed At Treating Solid Tumorsthe Company Collaborates With Major Pharmaceutical Partners Like Astrazeneca And Astellas Pharma To Enhance Its Product Development And Market Reachfibrogen Went Public In 2014 And Operates Globallywith A Strong Presence In Chinaeuropeand Japanthe Company Employs Around 225 People And Is Led By Ceo Thane Wettig
